received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking in January 2024. Dr. Uday N. Kumar, Founder, President, and CEO of Element Science, reflected on the achievement, "The Jewel Patch-WCD is...
technology platforms. Mr. Messerlian joined Creyon's Board of Directors as Executive Chairman and Acting CEO in early fall 2024. He brings extensive experience in company building and board leadership, having served in senior roles across multiple...
coming weeks. The CE Mark follows the recent approval of Optune Lua by the U.S. Food and Drug Administration in October 2024. Data Supporting the CE Mark of Optune Lua: The CE Mark approval was supported by data from the Phase 3 LUNAR trial that...
tumor-informed MRD solution for clinical use to support recurrence risk stratification. Labcorp Plasma Detect launched in 2024 for biopharma use to support exploratory and investigational studies. The test combines a WGS approach, without the need...
mobile-friendly, data-driven dashboard. The innovative system was first used shortly after achieving FDA clearance in late 2024 and has been rapidly adopted by likeminded organizations across the nation ever since. Now, over 12 OPOs stock the...
Director Dr. Gernot Wolfram. With more than 40 years of experience, RECIPE is a highly respected, profitable company with 2024 revenues of more than fifteen million dollars. The majority investment and strategic collaboration immediately enhances...
that dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade led to improved chemotherapy response (2024 American Society of Hematology Annual meeting : Poster #2758). This therapeutic approach is protected by an expanded...
nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s...
Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative...
introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'. Following these...
is a household name synonymous with healthy aging.” Niagen Bioscience recently reported its fourth quarter and full-year 2024 financial results, with strong full-year net sales at $99.6 million, up 19% from the prior year, and $44.7 million in cash...
Following this success, Medit introduced its best-selling i700 in 2021, i700 Wireless, and i600 in 2022, and i900 in 2024, providing a complete range of scanners for all types of dental practices. Medit is expanding its influence beyond intraoral...
a town in Poland to one of the greatest scientific centers in the United States," says Tomasz Nowakowski, winner of the 2024 Vilcek Prize for Creative Promise in Biomedical Science. "I am deeply grateful to [foundation founders] Jan and Marica...
Potent and Regular Potency). The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees. In 2022, CordenPharma was...
eligible uninsured patients through its Patient Assistance Program (PAP). IMKELDI, which received FDA approval in November 2024, is now available for order through specialty distribution partners in the U.S. IMKELDI’s advanced liquid formulation of...
States—prodisc C Vivo, prodisc C SK and prodisc C Nova. The prodisc C Nova product, released on a limited basis in October 2024, is the newest prodisc Cervical technology available in the U.S. Over 900 surgeons have used the Match-the-Disc system,...
symptom activity. Outcomes from the pivotal Phase 3 trial of Stanza were published in The Lancet in July 2024. This decision marks a significant step forward in increasing access to evidence-based, non-drug treatments for people with fibromyalgia,...
pan-European partnerships.” Mr. Omari will be based at Avanzanite’s second headquarters in Maastricht, the Netherlands. In 2024, Avanzanite continued its growth in the European orphan drug market, reaching over 120 patients across 12 countries and...
escalation cohorts with participants randomized to receive HB-500 or placebo. The first participant was dosed on July 1, 2024, and primary completion is expected in the second half of 2025. “HB-500 is designed to induce robust and durable immunity...
held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. "Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical...
